Xiang Li, PhD

Esketamine Nasal Spray Combined With an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression: Results of a Double-Blind, Randomized Withdrawal, Multicenter Study (SUSTAIN-1)

Background: Numerous studies have demonstrated short-term efficacy of esketamine in treatment-resistant depression (TRD), whereas long-term antidepressant effects remain to be established...

John Zajecka , MD;

Madhukar Trivedi , MD;

Andrew Winokur , MD, PhD;

Wayne Drevets , MD;

Ilona Divacka , MBA, MD;

Jaskaran Singh , MD;

Andrea Fagiolini , MD;

Wieslaw Cubala , MD, PhD;

Xiang Li , PhD;

Pierre Blier , MD, PhD;

Rosanne Lane , MD, MSc, MS;

Richard Shelton , MD;

Pilar Lim , MD, PhD;

Patricio Molero , MD, PhD;

David Hough , MD;

Husseini Manji , MD;

Istvan Bitter , MD, PhD, DSc;

Adam Janik , MD;

Michael Thase , MD;

Honglan Li , MD, PhD;

Yun Zhang , PhD;

Anna Ducca , BSN;

Ella Daly , MB, BCh, BAO;

03/01/2019

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Adult Patients at Imminent Risk for Suicide: ASPIRE-1, a Phase 3 Randomized Study

Introduction: ASPIRE-1 is one of two global phase-3 studies in the registration program to evaluate efficacy and safety of esketamine nasal spray (ESK) vs placebo, with comprehensive stan...

Dong Jing Fu , MD, PhD;

Carla M. Canuso , MD;